
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - Cutaneous lesions are common in infants with neonatal lupus erythematosus (NLE) and may have life-long sequelae. However, the most worrisome associations are its noncutaneous features and the increased risks for a mother to develop an autoimmune disorder herself, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.